Like companies in all industry sectors, many biotechnology and pharmaceutical companies are struggling to understand and find strategies to address the challenges presented by the COVID-19 outbreak. The impact of the pandemic on the conduct of clinical trials has forced both smaller biotechs and Big Pharma to make tough decisions to pause ongoing trials and reconsider timelines for data readouts, regulatory reviews, and product launches. As companies focus on the immediate impact of COVID-19 on their development efforts, industry insiders are considering what the longer-term implications will be and how to address them.
In this article, Angela De Martini, Dean Lockhead, and Leandra Plappert discuss various factors influencing the ability to advance clinical research programs as well as COVID-19’s impact on those programs and how new challenges are likely to reverberate throughout the industry.
To read the article in Clinical Leader, click here.
